• Home
  • Our Discovery
  • Market Opportunity
  • Management
  • Partnering
  • News
  • Legal Notices
  • Media
  • News Archive
  • More
    • Home
    • Our Discovery
    • Market Opportunity
    • Management
    • Partnering
    • News
    • Legal Notices
    • Media
    • News Archive
  • Home
  • Our Discovery
  • Market Opportunity
  • Management
  • Partnering
  • News
  • Legal Notices
  • Media
  • News Archive
Vivacelle Bio Inc.

FEBRUARY 21, 2023

 Hypovolemic Shock Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Pharmazz, Perfusion Medical, Vivacelle Bio

  

https://www.openpr.com/news/2920693/hypovolemic-shock-market-to-exhibit-moderate-growth-rate-during

The Hypovolemic Shock market is expected to surge due to the diseases increasing prevalence and awareness during the forecast period Furthermore launching various multiple stage Hypovolemic Shock pipeline products will significantly revolutionize the Hypovolemic Shock market dynamics DelveInsight s ...

 www.openpr.com 


FEBRUARY 9, 2023

 

Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

  

https://www.businesswire.com/news/home/20230209005014/en/Vivacelle-Bio%E2%80%99s-VBI-S-Phase-IIa-Clinical-Trial-Meets-Primary-and-Secondary-Endpoints-for-Treating-Hypovolemia-in-Septic-Shock-Patients


 KANSAS CITY, Mo.--(BUSINESS WIRE)--Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia. Severe septic shock patients experience a drastic drop in blood pressure that is associated with multiple organ failure causing patient death. While conventional fluids are effective for treating absolute hypovolemia, they are ineffective for treating relative hypovolemia, which is caused by excessive production of nitric oxide (NO) in septic shock. VBI-S, which is administered intravenously, reversibly absorbs NO, reducing the bioavailability of NO. This first of its kind approach reduces the bioavailability of NO without interfering with its production or essential cellular interactions. 


 www.businesswire.com 


Contacts

Harven DeShield, J.D., Ph.D., CEO
716-830-8932
harven@vivacellebio.com


October 20, 2022

  Vivacelle Bio Announces Early Results of its Phase IIa   Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis www.blackprwire.com 

(Black PR Wire) Kansas City, MO - Vivacelle Bio, Inc., a privately held company focused on the development of improved treatments for septic shock, today announced early results from its Phase IIa Clinical Trial of VBI-S in septic shock patients. Each of the thirteen (13) patients treated so far in the trial met the primary goal which was an elevation of mean arterial blood pressure by at least ...




September 21, 2022

Septic Shock Market is   Expected to Expand at a Healthy Growth Rate by (2022-2032), States   DelveInsight | Key Companies – Adrenomed AG, Vivacelle Bio, Inotrem - Digital   Journal

DelveInsight’s “Septic Shock Market Insights, Epidemiology,  and Market Forecast-2032″ report offers an in-depth understanding of the   Septic Shock,

www.digitaljournal.com  

MAY 9, 2022

Sepsis And Septic Shock Treatment Market Hitting New Highs By 2028 | VBI-S: Vivacelle Bio, Nangiboti

See the article here:   

https://www.digitaljournal.com/pr/sepsis-and-septic-shock-treatment-market-hitting-new-highs-by-2028-vbi-s-vivacelle-bio-nangibotide-lr12-inotrem-allocetra-enlivex-therapeuticsttps://beststartup.us/?p=6700 


June 23, 2021

Vivacelle Bio Nominated as a Top Biotechnology Company in Illinois by BestStartup.us

See the article here:  https://beststartup.us/?p=6700 


May 6, 2021

Vivacelle Bio prominently featured in Hypovolemic Shock Market: Market Analysis, Leading Companies

Hypovolemic Shock Market: Market Analysis, Leading Companies, Emerging Drugs, Epidemiology Forecast and Competitive Analysis by DelveInsight


https://www.bignewsnetwork.com/news/269270023/hypovolemic-shock-market-market-analysis-leading-companies-emerging-drugs-epidemiology-forecast-and-competitive-analysis-by-delveinsight 


 www.bignewsnetwork.com 


Feb 9, 2021

World Sepsis Pipeline Insight 2021: Pipeline Product Profiles, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs - ResearchAndMarkets .com

https://www.businesswire.com/news/home/20210209005785/en/World-Sepsis-Pipeline-Insight-2021-Pipeline-Product-Profiles-Therapeutic-Assessment-Pipeline-Assessment-Inactive-Drugs-Assessment-Unmet-Needs---ResearchAndMarkets.com

Nov. 24, 2020

FORT WAYNE, Ind., Nov. 24, 2020 /PRNewswire/

Vivacelle Bio Receives $5.3 Million Award from the US Navy for a Clinical Trial of VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens.

APRIL 29, 2020

VIVACELLE BIO GIVEN THE BUSINESS EXPANSION AWARD BY THE METRO CHAMBER ALLIANCE OF GREATER FORT WAYNE

APRIL 29, 2020

Black Doctor Says He Has Developed Clinical Treatment For COVID-19 Patients That Increases Oxygen Le

 https://www.blacknews.com/news/cuthbert-simpkins-black-doctor-clinical-treatment-covid-19-patients-increases-oxygen-levels/ 

February 6, 2020

APRIL 22, 2020

Vivacelle Bio Provides its Sepsis Treatment for COVID-19 Via Compassionate Use | 2020-04-22 | FDAnew

https://www.fdanews.com/articles/196749-vivacelle-bio-provides-its-sepsis-treatment-for-covid-19-via-compassionate-use

AprIL 21, 2020

"Vivacelle Bio Announces Compassionate Use for COVID-19 Patients with our Sepsis Treatment, VBI-S, for the elevation of blood pressure (treating persistently low hypotension) in Covid-19 induced Septic Shock.  Most COVID patients die of septic shock. In early studies, VBI-S improved blood pressure and oxygenation of septic shock patients when all other measures had failed.  See Press Release immediately below."

Vivacelle Bio Announces Compassionate Use for COVID-19 Patients with Its Sepsis Treatment, VBI-S

https://www.prnewswire.com/news-releases/vivacelle-bio-announces-compassionate-use-for-covid-19-patients-with-its-sepsis-treatment-vbi-s-301044045.html

Detail your services

If customers can’t find it, it doesn’t exist. Clearly list and describe the services you offer. Also, be sure to showcase a premium service.

Drop us a line!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivacelle Bio, Inc.

science@vivacellebio.com

Hours

Open today

09:00 am – 05:00 pm

Social

Our Partners

Copyright © 2023 Vivacelle Bio Inc. - All Rights Reserved.

Powered by GoDaddy Website Builder

  • Home
  • Market Opportunity
  • Management
  • News
  • Legal Notices

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept